MAZE

Maze Therapeutics, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000

$31.48Close $1.6BMarket cap $22.39 – $51.8352-week range Nov 5, 2026Next report

Highlights

Cautions

Not in an uptrend 2 of 8 trend conditions
Far from its high 39% below its 52-week high
Results soon Nov 5, 2026, in 4 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 11, 2026

Off 12-month high 39%

1wk 1.5% price change

1mo 15.8% price change

12-month return 5% market up 11% · its own down 10%

F-score — — Not assessed

Altman Z — Unknown

P/E — price / earnings

PEG — P/E / EPS growth

P/B 4.4× price / book

Earnings yield 10.5% EBIT / enterprise value

Cheaper than — of the market · not assessed

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE 37% return on equity

Free cash margin — -$112.7M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 4.9% $1.54 a day · 2×ATR $28.39

RS 51 / 99 vs the universe

Trend 2 / 8 trend template

Relative volume 0.4× vs 50-day average

Up/down volume 1.15 50 sessions

Implied move — no option chain · report Nov 5, 2026

Trend template · 2 of 8

Price above the 50-day average: passes
At least 30% above the 52-week low: passes

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Shareholders diluted The share count rose 1916.3% over the year, from 2m to 49m shares. Each existing share owns a smaller fraction of the company than it did a year ago.

Last reported Aug 11, 2026

Results reaction Aug 11, 2026+1% vs market2 sessions after results

Financials

2 fiscal years · from filings

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$131.1M down to a loss

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$112.7M down to a loss

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 49.34m +1916.3% since FY2024

	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$167.5M	—
Operating income	$57.6M	-$142.9M
Net income	$52.2M	-$131.1M
Net margin	31%	—
Earnings per share	$19.13	-$3.05
Free cash flow	$74.8M	-$112.7M
Free cash margin	45%	—
Cash	$196.8M	$189.2M
Shareholders' equity	-$311.2M	$355.0M
Shares outstanding	2.45m	49.34m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 11, 2026	Quarterly ↗	Jun 30, 2026	42d
May 12, 2026	Quarterly ↗	Mar 31, 2026	42d
Mar 25, 2026	Annual ↗	Dec 31, 2025	84d
Nov 6, 2025	Quarterly ↗	Sep 30, 2025	37d
Aug 12, 2025	Quarterly ↗	Jun 30, 2025	43d
May 14, 2025	Quarterly ↗	Mar 31, 2025	44d

Current reports

Filed	Disclosed
Oct 16, 2026	Material agreement · Unregistered share sale ↗
Aug 17, 2026	Director or officer change · Regulation FD ↗
Aug 11, 2026	Results ↗
Jun 10, 2026	Shareholder vote ↗
May 22, 2026	Director or officer change ↗
May 12, 2026	Results ↗
Apr 22, 2026	Other events ↗
Mar 25, 2026	Results · Director or officer change · Regulation FD ↗
Feb 4, 2026	Material agreement · Agreement ended · New obligation ↗
Nov 6, 2025	Results ↗
Oct 6, 2025	Director or officer change ↗
Sep 11, 2025	Material agreement · Unregistered share sale · Regulation FD ↗